Article

New use permitted: FDA approves latanoprost as first-line IOP reducer

Peapack, NJ-Pharmacia Ophthalmology will begin making its latanoprost ophthalmic solution(Xalatan) available for initial treatment of elevated eye pressure associated with open-angle glaucoma or ocular hypertension.

Related Videos
2 experts are featured in this series.
Related Content
Study reveals growing treatment burden of retinal diseases in Finland
December 24th 2024

Study reveals growing treatment burden of retinal diseases in Finland

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Advanced therapies for retinal vascular diseases
December 23rd 2024

Advanced therapies for retinal vascular diseases

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

Curacle presents results of its phase 2a clinical trial of CU06 for DME
December 20th 2024

Curacle presents results of its phase 2a clinical trial of CU06 for DME

© 2024 MJH Life Sciences

All rights reserved.